Israel Englander Monte Rosa Therapeutics, Inc. Transaction History

Millennium Management LLC

$213 Billion
Q3 2025

A detailed history of Israel Englander (Millennium Management LLC) transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 444,939 shares of GLUE stock, worth $6.39 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

444,939

Previous 64,631 588.43%

Holding current value

$6.39 Million

Previous $291,000 1032.65%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$4.19 - $7.49 $1.59 Million - $2.85 Million	380,308 Added 588.43%	444,939 $3.3 Million
Q2 2025 Aug 14, 2025	SELL	$3.7 - $5.33 $983,593 - $1.42 Million	-265,836 Reduced 80.44%	64,631 $291,000
Q1 2025 May 15, 2025	BUY	$4.64 - $7.17 $1.32 Million - $2.04 Million	284,097 Added 612.67%	330,467 $1.53 Million
Q4 2024 Feb 14, 2025	BUY	$4.8 - $10.36 $75,595 - $163,159	15,749 Added 51.43%	46,370 $321,000
Q3 2024 Nov 14, 2024	BUY	$3.59 - $6.97 $34,797 - $67,560	9,693 Added 46.32%	30,621 $162,000

Q2 2024 Aug 14, 2024	SELL	$3.38 - $7.86 $436,347 - $1.01 Million	-129,097 Reduced 86.05%	20,928 $78,000
Q1 2024 May 15, 2024	BUY	$4.26 - $8.46 $352,497 - $700,031	82,746 Added 122.99%	150,025 $1.06 Million
Q4 2023 Feb 14, 2024	BUY	$2.5 - $5.93 $168,197 - $398,964	67,279 New	67,279 $380,000
Q1 2023 May 15, 2023	SELL	$5.95 - $8.21 $1.64 Million - $2.27 Million	-276,056 Reduced 70.22%	117,094 $912,000
Q4 2022 Feb 14, 2023	BUY	$6.71 - $9.72 $2.46 Million - $3.57 Million	367,221 Added 1416.26%	393,150 $2.99 Million
Q3 2022 Nov 14, 2022	BUY	$7.17 - $12.16 $61,131 - $103,676	8,526 Added 48.99%	25,929 $212,000

Others Institutions Holding GLUE

# of Institutions

132

Shares Held

55.7M

Call Options Held

159K

Put Options Held

269K

View Full List

About Monte Rosa Therapeutics, Inc.

Ticker GLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,713,900
Market Cap $671M
Description
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...

More about GLUE

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account